AiCuris Seeks Partners For Antibacterial Programs

AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago.

Video interview
• Source: Shutterstock

AiCuris GMBH & Co. KG CEO Holger Zimmermann highlights AiCuris's anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans.

AiCuris already has an exclusive worldwide licensing agreement in place with Merck & Co. Inc. for its lead compound,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.